Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231. - Archive ouverte HAL Access content directly
Journal Articles Pharmaceutical Research Year : 2009

Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231.

(1, 2) , (1) , (1) , (1) , (2) , (1) , (1)
1
2

Abstract

PURPOSE: The aim of this study is to overcome tumour cell resistance that generally develops after administration of commonly used anti-cancer drugs, such as doxorubicin. METHODS: Recently, cell penetrating peptides have been used for their ability to deliver non-permeant compounds into cells. One such cell penetrating peptide, maurocalcine, has been isolated from the venom of a Tunisian scorpion. Herein, we report the effects of doxorubicin covalently coupled to an analogue of maurocalcine on drug-sensitive or drug-resistant cell lines MCF7 and MDA-MB 231. RESULTS: We demonstrated the in vitro anti-tumoral efficacy of the doxorubicin maurocalcine conjugate. On a doxorubicin-sensitive cancer cell line, the maurocalcine-conjugated form appears slightly less efficient than doxorubicin itself. On the contrary, on a doxorubicin-resistant cancer cell line, doxorubicin coupling allows to overcome the drug resistance. This strategy can be generalized to other cell penetrating peptides since Tat and penetratin show similar effects. CONCLUSION: We conclude that coupling anti-tumoral drugs to cell penetrating peptides represent a valuable strategy to overcome drug resistance.
Fichier principal
Vignette du fichier
PhR_aroui_manuscript_revision_with_fig_vfinale.pdf (326.4 Ko) Télécharger le fichier
Vignette du fichier
inserm-00356481_edited.pdf (1.86 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00356481 , version 1 (09-02-2009)

Identifiers

Cite

Sonia Aroui, Narendra Ram, Florence Appaix, Michel Ronjat, Abderraouf Kenani, et al.. Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231.. Pharmaceutical Research, 2009, 26 (4), pp.836-45. ⟨10.1007/s11095-008-9782-1⟩. ⟨inserm-00356481⟩

Collections

INSERM UGA U836
314 View
684 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More